Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Monte Rosa Therapeutics, Inc. is set to present at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its focus on developing novel molecular glue degrader (MGD)-based medicines for serious diseases [1] Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company specializing in highly selective molecular glue degrader (MGD) medicines targeting oncology, autoimmune, and inflammatory diseases [3] - The company utilizes its QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine, which integrates AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify and design MGDs with high selectivity [3] - Monte Rosa has established a leading pipeline of MGDs and has global licensing agreements with Novartis and strategic collaborations with Roche to develop MGDs for cancer and neurological diseases [3]